FDA Brief

Warning letters Food

FDA warning letter to

Nuturna International LLC

High riskIssued Sep 7, 2021Posted Sep 9, 2021Center for Food Safety and Applied Nutrition (CFSAN)

Nuturna International marketed 'Diabetic Support Formula' with diabetes-treatment claims, making it an unapproved drug and misbranded.

What happened

In August 2021, FDA reviewed Nuturna's website and its Amazon storefront and product page. FDA found testimonials and claims that 'Diabetic Support Formula' lowers blood sugar and treats or prevents diabetes. FTC also reviewed the websites in August 2021 and demanded that the company stop making diabetes claims without competent and reliable scientific evidence.

What FDA found

  1. The website and Amazon page claims and testimonials show the product is intended to treat, prevent, or mitigate diabetes, so it is a drug.

    Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The product is an unapproved new drug because it is not generally recognized as safe and effective for those uses and has no FDA approval.

    Sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The product is misbranded because it lacks adequate directions for safe use by a layperson for diseases that require a licensed practitioner.

    Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 C.F.R. 201.5
  4. Introducing or delivering the misbranded drug into interstate commerce violates the Act.

    Section 301(a) of the Act [21 U.S.C. 331(a)]
  5. FTC says the company must stop claiming a product can prevent, treat, or cure diabetes unless it has competent and reliable scientific evidence, including well-controlled human clinical studies.

    FTC Act, 15 U.S.C. ยง 41 et seq.

What FDA wants

FDA asks Nuturna to notify it in writing within 15 working days of receipt of the specific steps taken to address the violations, including explanations and documentation; if corrective actions cannot be completed in that time, state why and when they will be done.

Who should pay attention

  • dietary supplement brands making disease-related claims
  • Amazon sellers and website marketers of supplements
  • companies advertising diabetes or blood sugar products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk